Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTopical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma
International Journal of STD & AIDS, 09/30/08
De Socio GVL et al. - The authors describe a 42-year-old man with AIDS and Hodgkin's lymphoma whose severe and recalcitrant cutaneous warts resolved following treatment with local 1% cidofovir. Clinically significant improvements were observed in a two-week period of therapy. In advanced HIV disease complicated by additional haematological malignancy, cutaneous warts may be difficult to treat and present a challenge for the attending physicians.
Related Articles
Testing the susceptibility of human herpesviruses to antivirals
Future Microbiology, 11/18/09
Relevance Score: 80%
Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet
Pediatric Transplantation, 11/04/09
Relevance Score: 80%
Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus
Journal of Virology, 10/26/09
Relevance Score: 80%
Newer trends in the management of genital herpes
Indian Journal of Dermatology, Venereology and Leprology, 11/18/09
Relevance Score: 77%
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures
Medicinal Research Reviews, 10/21/09
Relevance Score: 77%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatic profile analyses of tipranavir in Phase II and III clinical trials
BMC Infectious Diseases, 12/16/09
Use of oseltamivir in children
Canadian Family Physician, 12/16/09
Investigational drugs for hepatitis C
Expert Opinion on Investigational Drugs, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor